Press Release Details

Brand India Pharma makes an impacting presence at CPhI Japan 2015

New Delhi, April 22, 2015: A strong delegation of major Indian pharmaceutical companies led by Pharmaceutical Export Promotion Council of India (Pharmexcil) has made an impacting presence at CPhI Japan 2015. CPhI Japan was inaugurated today at a glittering ceremony at the Big Sight Exhibition Centre in Tokyo, Japan. Mr. Amit Kumar, Deputy Chief of Mission at the Embassy of India in Japan co-inaugurated the Event. Pharmexcil has planned a series of activities at CPhI Japan under the Brand India Pharma campaign.

Comprising names like Reva Pharmachem, Suven Life Sciences, IndSwift Labs, Jubiliant Life Sciences, Laurus Labs, Aurobindo Pharma, Vimta Labs and Simpex Pharma, a total of 18 pharma companies from India are participating at CPhI Japan 2015 as part of the official delegation. A seminar titled India-Japan Pharma Summit was held on April 22, 2015 in Tokyo on the sidelines of the Exhibition. With a special focus on the 'Make in India' programme of the Government of India, the Seminar received an overwhelming response from Japanese companies with over 400 registrations.

The India-Japan Pharma Summit attracted participation from the Department of Commerce, Government of India, Pharmexcil, Ministry of Health, Labour & Welfare) Government of Japan, Dr Gurpreet Sandhu, Managing Director, Reva Pharmachem, Dr. Vijay Kaiwar, Head of Contract Research and Manufacturing Services (CRAMS) Business, Aurobindo Pharma, Dr. Masafumi Yamagishi, Ph.D. Associate Director, Division Deputy Manager, CMC Division, Mitsubishi Tanabe Pharma Corporation, Mr. Makoto Shigemitsu, Director, GMP Inspection, Office of GMP/QMS Inspection, Meiji Seika Pharma Co. Ltd, Mr. Masatoshi Morisue, Director, Office of Manufacturing /Quality and Compliance, PMDA and Ms Sayoko Sasaki, Corporate Officer, Vice President, Corporate Affairs, Eisai Co Ltd. Pharmexcil also recognised select Japanese companies who are doing business with Indian companies for their contributions to Indian pharma industry.

"To begin with we plan to market APIs to Japanese Generic and Innovation companies. We have filed 27 numbers of JDMFs for several customers to supply them APIs as per the Japanese quality requirements. Further we plan to increase our number of JDMFs to enable us to increase our market share in the Japanese Pharmaceutical market," said Dr Vijay Kaiwar, Vice President - Business Development, AuroSource (A Division of Aurobindo Pharma Ltd).

"Our current engagement with the Japanese market is primarily for the contract manufacture of advance intermediates for drugs under clinical development/about to be commercial. Our interest and plan is to pursue similar business viz., GMP, non-GMP custom synthesis/ contract, manufacture of intermediates and APIs of both new & marketed drugs. We have just started doing some generics business in Japan and would like to strengthen that in the future," said Mr Chandrakanth, Vice President & Head (Synthesis Division - Contract Development), Laurus Labs Pvt. Ltd.

"Japanese Pharmaceutical market created a mystic aura of uniqueness for their quality system requirement, restricting and reducing mushrooming of competitors with compromising quality compliances. Suven is engaged in providing quality intermediates to the Japanese innovator companies during the last 7 years. We also filed DMFs with PMDA and obtained its accreditation. Our services are well appreciated by the customers," said Mr Mohan Rao Manam, Vice President - Business Development & Regulatory Affairs, Suven Life Sciences Ltd.

Apart from the seminar, Pharmexcil has also partnered with UBM, the organiser of CPhI Japan, for the CPhI Japan 2015 reception. The Reception will include a cultural performance on India and a film on the Indian pharmaceutical industry. The focused activities under the Brand India Pharma campaign are expected to further increase India-Japan cooperation in the pharmaceutical sector.

About Brand India Pharma:

Brand India Pharma campaign is a significant initiative being led by India Brand Equity Foundation (IBEF) and Pharmaceutical Export Promotion Council (Pharmexcil) under the aegis of the Department of Commerce, Government of India, to highlight the value proposition that Brand India Pharma presents today globally. Synonymous with Credible, Affordable and Sustainable healthcare, the Brand India Pharma campaign was launched at CPhI Japan in March 2012.

For any queries, please contact:
Pawan Chabra
Manager - Knowledge Centre
India Brand Equity Foundation
+91 124 4499610
pawan.chabra@ibef.org

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...